Cardio-oncology Related to Heart Failure, An Issue of Heart Failure Clinics

As the number of effective anti-neoplastic agents has grown, there has been a concomitant increase in side effects.� Cardiotoxicity, and specifically LV dysfunction, remains the limiting factor for many such agents, and is the focus of growing research and clinical emphasis.� This issue summarizes for the heart failure specialist the possible ways that chemotherapeutic agents might cause cardiotoxicity as well as the methods for detecting, treating and preventing cardiotoxicity.